Shilpa Medicare Limited, Unit IV, Jadcherla, Telangana, India and Shilpa Medicare Ltd, Unit VII, Nacharam, Hyderabad, Telangana, India had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union (EAEU) in October 2024.
Both units of Shilpa Medicare Ltd (Unit IV and Unit VII), have now received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan and Armenia.
This approval will open up significant business opportunities in these countries.
Unit IV of Shilpa Medicare Lid. is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets.
Unit VII of Shilpa Medicare Ltd. is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.
Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 768.70 as compared to the previous close of Rs. 764.75. The total number of shares traded during the day was 10144 in over 477 trades.
The stock hit an intraday high of Rs. 777.45 and intraday low of 759.60. The net turnover during the day was Rs. 7807968.00. |
